ABL Bio, Inc. 298380
KRX · South Korea · Health Technology
KRW 53,600.00+5,100.00 (+10.52%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
DelveInsight's Bispecifics Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Rheumatoid Arthritis, Systemic Lupus Erythema
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H
ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company ("Lilly").
As global markets navigate a complex landscape marked by dovish Federal Reserve signals and mixed economic data, investors are keenly observing growth companies with high insider ownership as potential opportunities. In such a climate, stocks that combine robust growth prospects with strong insider commitment can offer unique insights into the confidence of those closest to the company's operations.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.